Gomez G A, Sokal J E
Cancer Treat Rep. 1979 Aug;63(8):1385-7.
Vinblastine (6 mg/m2) was given to 15 patients in the terminal phase of Ph1 chromosome-positive chronic myelocytic leukemia and to one patient with chronic myelomonocytic leukemia. In each of these patients, there was prompt reduction in leukocyte counts (median, 80% decrease). Effects on platelet counts and hematocrit levels were inconsistent. Nine patients had decreases in the percentage of circulating blast cells. Reduction in splenomegaly and relief of bone pain were recorded in patients with these manifestations. Serious leukopenia was induced in only one patient, and was of brief duration. Additional doses of vinblastine at intervals of greater than or equal to 3 weeks were given to eight patients who had shown improvement in the differential cell count, as an adjunct to maintenance schedules of combination chemotherapy. Good results were obtained initially, but the quality and duration of responses decreased after two to six injections.
长春花碱（6毫克/平方米）被给予15例处于费城染色体阳性慢性粒细胞白血病终末期的患者以及1例慢性粒单核细胞白血病患者。在这些患者中，每例的白细胞计数均迅速下降（中位数下降80%）。对血小板计数和血细胞比容水平的影响并不一致。9例患者循环原始细胞百分比下降。有脾肿大和骨痛表现的患者出现了脾肿大缩小和骨痛缓解。仅1例患者发生了严重白细胞减少，且持续时间短暂。对于8例在细胞分类计数中显示病情改善的患者，每隔3周或更长时间给予额外剂量的长春花碱，作为联合化疗维持方案的辅助治疗。最初取得了良好效果，但在注射两至六次后，反应的质量和持续时间下降。
